Galera Therapeutics Aramchol NASH 2016 Corporate Presentation

Galera Therapeutics presented progress on Aramchol, a clinical-stage drug candidate for NASH (non-alcoholic steatohepatitis) with demonstrated efficacy in reducing liver fat content. The company highlighted its experienced leadership team, proven track record in drug development, and plans for a Phase IIb trial with 240 patients expected by December 2016.